Inceptor Bio
2450 Perimeter Park Dr #200
Morrisville
NC
27560
United States
Website: https://www.inceptor.bio/
Email: info@inceptor.bio
About Inceptor Bio
Company Mission and Values
At Inceptor Bio, we have a vision to advance cell and gene therapies to cure difficult-to-treat cancers-improving and saving the lives of millions. Our values are:
- COMMITTED-We are a team committed to the relentless pursuit of curing cancer.
- URGENCY-We operate with an urgency to improve outcomes for our patients.
- RESILIENCE-We will rise to challenges and overcome difficulties.
- EMPOWERMENT-We empower each other to make decisions and create our own actions that lead to our collective goal.
What does it take to work at Inceptor Bio?
- TEAM SPRIT-We show up for each other, and our patients! We act with empathy and bring our authentic selves to work every day.
- ENTHUSIASM/PASSION-We approach our work and every challenge with enthusiasm, energy, and excitement. We take pride in our work and have fun while doing it!
- INITIATIVE-We anticipate potential issues and resolve them. We don’t wait to be asked to contribute. We see something that needs to get done and we do it with a positive attitude.
Everyone Belongs
Inceptor Bio is committed to creating and maintaining a workplace in which all employees have an opportunity to participate and contribute to the success of the business and are valued for their skills, experience, and unique perspectives.
We are committed to providing and promoting a diverse and inclusive environment for all, within which each person can succeed. We foster understanding, communication, and respect among all people in the company to create an inclusive workplace.
Check out our Ori Spotlight interview on Spotify
Jason C. Foster sits down with Mike Nicholson (President and Chief Operating Officer) and Matt Haines (Vice President of Manufacturing Operations) at Inceptor Bio, as they share their insights into the cell and gene therapy space.
10 articles about Inceptor Bio
-
Women are often at the forefront of innovation, making up nearly half of the life sciences industry despite a shrinking but persistent wage gap. Inceptor Bio is at the forefront of closing inequality. -
Inceptor Bio Announces Strategic Collaboration with University of Minnesota to Develop Novel iPSC Platform for the Advancement of Next-Generation Allogeneic Cell Therapies
6/30/2022
Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, today announced a collaboration with University of Minnesota.
-
Private investors, governmental institutions and longtime life sciences investors provided funding to develop therapies for cancers, dermatological problems and acute ischemic strokes. -
Fueled by $37 million in Series A financing, N.C.-based Inceptor Bio is advancing three, next-generation approaches to immuno-oncology, including a CAR-T program that is expected to be in the clinic next year. -
Inceptor Bio Announces $37 Million Series A Financing to Develop Cell Therapies for Difficult-to-Treat Cancers
5/19/2022
Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, today announced the closing of a $37 million Series A financing led by Kineticos Ventures.
-
Inceptor Bio Enters into In-licensing Agreement with University of California, Santa Barbara For CAR-M Platform
12/16/2021
Inceptor Bio today announced that it has executed an in-licensing agreement with the University of California, Santa Barbara (UCSB) for an investigational Chimeric Antigen Receptor Macrophage (CAR-M) therapy targeting difficult-to-treat tumors.
-
Inceptor Bio Announces Agreement to Acquire Gainesville, FL GMP Facility And Transfer Operating Team From Arranta Bio To Accelerate Cell Therapies To Cure Cancer
10/27/2021
Inceptor Bio ("Inceptor"), today announced an agreement with Arranta Bio ("Arranta") for the acquisition of a 29,000 ft2 process development and GMP clinical manufacturing facility and the transfer of a core operating team to establish cell therapy processes and clinical supply for Inceptor Bio's planned oncology clinical trials.
-
Inceptor Bio Announces The Appointment Of Dr. Mark J. Gilbert As Chair Of Its Scientific Advisory Board
7/28/2021
Inceptor Bio, a Research Triangle Park, North Carolina-based cell and gene therapy biotechnology company, announced the appointment of Dr. Mark J. Gilbert as Chair of its Scientific Advisory Board – leading a team of cell and gene therapeutics experts as scientific advisors to the company.
-
Inceptor Bio Launches FastBack Bio, Its First Portfolio Company Developing A Novel CAR-T Platform That Targets Difficult-To-Treat Cancers
7/7/2021
Inceptor Bio, a Research Triangle Park, North Carolina-based cell and gene therapy biotechnology company, announced that it has launched FastBack Bio, the first of multiple next-generation cell and gene therapy platform companies that Inceptor Bio is building.
-
Inceptor Bio Launches Next-Generation CAR-T, CAR-M, and NK/NKT Platform Focused on Advancing Cell and Gene Therapies to Cure Difficult-To-Treat Cancers
6/14/2021
Inceptor Bio, a Research Triangle Park, North Carolina-based cell and gene therapy biotech, announced that it is developing multiple next-generation cell and gene therapy platforms to cure difficult-to-treat cancers.